Evidence map›Paper›PMID 39962548›Full record

ArticleAnnals of clinical microbiology and antimicrobials2025

Host DNA depletion assisted metagenomic sequencing of bronchoalveolar lavage fluids for diagnosis of pulmonary tuberculosis.

Jinfeng Yuan, Liping Ma, Juan Du, Hailin Sun, Shanshan Li, Gang Zhou, Guanhua Rao, Fengshuo Sun, Wangyang Chen, Hui Miao and 6 more

Abstract read
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jinfeng Yuan *Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Liping Ma *Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, China.
Juan Du *Department of Tuberculosis, Wuhan Pulmonary Hospital, Wuhan, China.
Hailin Sun *Department of Tuberculosis, Ordos Second People's Hospital, Ordos, China.
Shanshan LiDepartment of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Gang ZhouGenskey Medical Technology Co., Ltd, A212 Innovation Building, Changping Life Garden, Beijing, China.
Guanhua RaoGenskey Medical Technology Co., Ltd, A212 Innovation Building, Changping Life Garden, Beijing, China.
Fengshuo SunGenskey Medical Technology Co., Ltd, A212 Innovation Building, Changping Life Garden, Beijing, China.
Wangyang ChenGenskey Medical Technology Co., Ltd, A212 Innovation Building, Changping Life Garden, Beijing, China.
Hui MiaoGenskey Medical Technology Co., Ltd, A212 Innovation Building, Changping Life Garden, Beijing, China.
Dan TianDepartment of Tuberculosis Prevention, Wuhan Pulmonary Hospital, Wuhan, Hubei, China.
Changhao ChengDepartment of Tuberculosis, Wuhan Pulmonary Hospital, Wuhan, China.
Yan WangDepartment of Tuberculosis, Ordos Second People's Hospital, Ordos, China.
Liang LiClinical Center On Tuberculosis Control, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China. Liliang69@vip.sina.com.
Lifeng LiGenskey Medical Technology Co., Ltd, A212 Innovation Building, Changping Life Garden, Beijing, China. lf.li@genskey.com.
Yu PangDepartment of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China. pangyupound@163.com.

Funding

Capital's Funds for Health Improvement and Research 2024-1-1041Capital's Funds for Health Improvement and Research 2024-4-1042
6 · The paper itself

Abstract

Metagenomic next-generation sequencing (mNGS) has greatly improved our understanding of pathogens in infectious diseases such as pulmonary tuberculosis (PTB). However, high human DNA background (> 95%) impedes the detection sensitivity of mNGS in identifying intracellular Mycobacterium tuberculosis (MTB), posing a pressing challenge for MTB diagnosis. Therefore, there is an urgent need to improve MTB diagnosis performance in PTB patients. In this study, we optimized mNGS method for diagnosis of PTB. This led to the development of the host DNA depletion assisted mNGS (HDA-mNGS) technique, which we compared with conventional mNGS and the host DNA depletion-assisted Nanopore sequencing (HDA-Nanopore) in diagnostic performance. We collected 105 bronchoalveolar lavage fluid (BALF) samples from suspected PTB patients across three medical centers to assess the clinical performance of these methods. The results of our study showed that HDA-mNGS had the highest sensitivity (72.0%) and accuracy (74.5%) in PTB detection. This was significantly higher compared to mNGS (51.2%, 58.2%) and HDA-Nanopore (58.5%, 62.2%). Furthermore, HDA-mNGS provided an increased coverage of the MTB genome by up to 16-fold. Antibiotic resistance gene analysis indicated that HDA-mNGS could provide increased depth to the detection of Antimicrobial resistance (AMR) locus more effectively. These findings indicate that HDA-mNGS can significantly improve the clinical performance of PTB diagnosis for BALF samples, offering great potential in managing antibiotic resistance in PTB patients.

Indexed as

Bronchoalveolar Lavage FluidMetagenomicsMycobacterium tuberculosisTuberculosis, PulmonaryAdultDNA, BacterialFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedNanopore SequencingSensitivity and SpecificityDNA, BacterialBronchoalveolar lavage fluidDrug resistanceHost DNA depletionMetagenomic next-generation sequencingPulmonary tuberculosis

Identifiers

PMID39962548
PMCPMC11834276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.